Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
Dyne Therapeutics (Nasdaq: DYN) has announced that its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 6, 2024, at 3:00 p.m. ET.
The event will be live-streamed on Dyne's website, with a replay available for 90 days. Dyne Therapeutics is a clinical-stage company focused on developing treatments for genetically-driven muscle diseases.
- Management's participation in a high-profile conference provides increased visibility for Dyne Therapeutics.
- The live webcast and 90-day replay availability can extend the reach to a broader audience, including potential investors.
- The presentation may provide updates on clinical trials or business developments, which could positively influence investor sentiment.
- The announcement does not include specific financial or clinical updates, which may leave investors seeking more concrete information.
- The stock performance might not significantly improve solely based on the participation in the conference without substantial news.
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024 at 3:00 p.m. ET.
A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.
About Dyne Therapeutics
Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contact:
Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203
FAQ
What is Dyne Therapeutics' stock symbol?
When is Dyne Therapeutics presenting at the Jefferies Global Healthcare Conference?
Where can I watch Dyne Therapeutics' presentation at the Jefferies Global Healthcare Conference?
How long will the replay of Dyne Therapeutics' presentation be available?
